What is Medpace Holdings's latest dividend and current dividend yield?

What were the key takeaways from Medpace Holdings’s earnings call?

What is Medpace Holdings's gross profit margin?

Did Medpace Holdings beat or miss consensus estimates last quarter?

What factors drove the changes in Medpace Holdings's revenue and profit?

What were the key takeaways from Medpace Holdings's earnings call?

What is the revenue and EPS growth rate for Medpace Holdings year over year?

What is the market's earnings forecast for Medpace Holdings next quarter?

- **Revenue Growth Strong**: Q4 2025 revenue up 32% YoY to $708.5M, driven by 39% YoY growth in net new business awards.
- **Cancellations Impact**: Q4 cancellations highest in over a year, but CEO expects normalization; metabolic trials disproportionately affected.
- **2026 Guidance Robust**: Revenue growth 8.9%-12.8%, EBITDA growth 8.5%-13.9%, with AI investments positioning for long-term efficiency.
- **Financial Discipline**: Cash flow of $192.7M in Q4 and $821M remaining under share buyback program.
- **Risk Note**: Concentration in metabolic trials (41%-42% of revenue) poses short-term margin pressure but expected to normalize.

**【CEO Summary Section】**
- Q4 2025 cancellations were the highest in over a year, resulting in a net book-to-bill ratio of 1.04. CEO August Troendle noted this was an anomaly and expects normalization in 2026.
- Backlog conversion rate of 23.6% highlights the company's ability to generate revenue from existing contracts despite lower book-to-bill.
- CEO emphasized a positive business environment with continued opportunities, though cautioning against over-reliance on cancellations trends.

**【President's Financial Overview】**
- Q4 2025 revenue: $708.5M (32% YoY growth); Full Year 2025: $2.53B (20% YoY growth).
- Net new business awards in Q4: $736.6M (39.1% YoY growth); Full Year 2025: $2.65B (18.7% YoY growth).
- Ending backlog: $3.0B (4.3% YoY growth); 12-month backlog conversion: $1.9B.

**【CFO Financial Commentary】**
- Q4 2025 EBITDA: $160.2M (20% YoY growth); Full Year EBITDA: $557.7M (16.1% YoY growth).
- 2026 Guidance:
  - Revenue: $2.755B-$2.855B (8.9%-12.8% YoY growth).
  - EBITDA: $605M-$635M (8.5%-13.9% YoY growth).
  - EPS: $16.68-$17.50 (11.3%-15.7% YoY growth).
- CFO Kevin Brady highlighted cost control, with cash flow from operations at $192.7M in Q4 and $821.7M remaining under share repurchase program.

**【Q&A Highlights】**
- **Cancellations & Metabolic Trials**: Elevated cancellations in Q4 were concentrated in metabolic programs (e.g., diabetes, obesity), which also drove higher pass-through costs. Management expects metabolic mix to normalize in 2026.
- **AI Strategy**: Early-stage AI rollouts focus on efficiency improvements (e.g., site selection, data analytics). CEO Troendle cautioned AI's long-term impact on margins but emphasized potential productivity gains.
- **Margin Dynamics**: 2026 EBITDA margin expected to remain stable (~22%), supported by slower hiring (mid-single-digit headcount growth) and retention-driven productivity.
- **Competitive Landscape**: No material change in competitive dynamics; top CROs remain active but no significant impact on win rates.


Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 2025 revenue $659.9M (+23.7% YoY), net new awards $789.6M (+47.9% YoY).
- **Profitability**: EBITDA $148.4M (+24.9% YoY), net income $111.1M (+15.3% YoY), EBITDA margin 22.5%.
- **2026 Outlook**: Low double-digit revenue growth, high single-digit EBITDA growth, pass-through costs 41-42% of revenue.
- **Pass-Through Dynamics**: 2025 pass-through costs 42%, expected to moderate in 2026 as trials progress.
- **Competitive Position**: Stable win rates, 30%+ of revenue from metabolic studies (GLP-1 dominant but diverse pipeline).

**【CEO Opening Remarks】**
- Q3 2025 net bookings and net book-to-bill of 1.20, with awarded work up 30% YoY.
- 2026 guidance: Revenue growth in low double digits, EBITDA in high single digits, pass-through costs at 41-42% of revenue.
- 2025 updated guidance: Revenue $2.48-2.53B (17.6-20% growth), EBITDA $545-555M (13.5-15.6% growth), EPS $14.60-14.86.

**【President's Financial Summary】**
- Q3 revenue $659.9M (+23.7% YoY), net new business awards $789.6M (+47.9% YoY), backlog conversion 23% of beginning backlog.
- Year-to-date revenue $1.82B (+15.9% YoY), EBITDA $397.5M (+14.7% YoY), EBITDA margin 21.8% vs 22% prior year.

**【CFO Financial Commentary】**
- Q3 EBITDA $148.4M (+24.9% YoY), net income $111.1M (+15.3% YoY), EPS $3.86 vs $3.01 prior year.
- Cash flow from operations $246.2M, share repurchases $4.5M Q3, $912.9M YTD.
- 2025 full year EBITDA margin 21.8%, driven by productivity and cost control offset by higher reimbursable costs.

**【Q&A Highlights】**
- Pass-through costs expected to peak in Q4 2025, then moderate in 2026 due to late-stage trial timing.
- 2026 revenue growth driven by metabolic studies (30%+ of revenue), with GLP-1 dominant but non-GLP-1 contributors.
- Competitive environment stable, win rates maintained despite increased bidding activity.
- Headcount growth accelerating into 2026 to support backlog conversion, hiring focused in US and India.

Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript

- **Revenue Growth Acceleration**: Q2 revenue up 14.2% YoY, with full-year guidance raised to $2.42–$2.52 billion, driven by faster-burning studies and lower cancellations.
- **Profitability Expansion**: EBITDA margin of 21.6% and net income of $90.3 million reflect strong cost control and operational efficiency.
- **Reimbursable Cost Surge**: Reimbursable costs as a percentage of revenue expected to rise 200–300 bps YoY, fueling higher burn rates and revenue growth.
- **Share Buyback Momentum**: $908.4 million repurchased year-to-date, with $826.3 million remaining under authorization.
- **Key Risks**: 2026 growth hinges on funding stability and new awards, with potential for elevated cancellations if macro conditions worsen.

**【CEO Summary Section】**
- **Revenue Growth and Guidance Update**: Q2 revenue of $603.3 million (+14.2% YoY), with full-year guidance raised by $280 million midpoint to $2.42–$2.52 billion. Book-to-bill ratio of 1.03x in Q2, with potential to exceed 1.15x in Q3.
- **Pipeline Dynamics**: Pending RFP dollars declined, awards reached highest level in 5 quarters, and cancellations were significantly lower. Shift to faster-burning therapeutic areas (e.g., metabolic) drove higher reimbursable costs, expected to increase 200–300 basis points YoY.
- **Funding Environment**: Stable to improving funding for ongoing studies, though challenges remain for new trials.

**【CFO Financial Commentary】**
- **Profitability**: EBITDA of $130.5 million (+16.2% YoY), EBITDA margin 21.6%, and net income of $90.3 million (+2.2% YoY). Non-GAAP EPS of $3.10 exceeded expectations.
- **Cash Flow and Share Repurchases**: $148.5 million in Q2 operating cash flow, with $908.4 million repurchased year-to-date. $826.3 million remaining under share buyback authorization.
- **Updated Guidance**: Full-year EBITDA expected at $515–$545 million (+7.3%–13.5% YoY), driven by lower cancellations and faster-burning studies.

**【Q&A Highlights】**
- **Booking Expectations**: CEO August Troendle emphasized potential for book-to-bills >1.15x in Q3, contingent on stable cancellations and funding.
- **Burn Rate and Reimbursables**: CFO Kevin Brady noted 200–300 bps increase in reimbursable costs as a percentage of revenue, contributing to higher burn rates and revenue growth.
- **Funding and Cancellations**: Cancellations were unusually low in Q2, but risks remain for 2026 if funding weakens. Management expects 2026 bookings to depend on new awards and cancellation trends.
- **Hiring and Productivity**: Accelerated hiring in H2 (mid-single-digit growth) to support demand, with improved attrition rates offsetting some headwinds.


Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 revenue up 9.3% YoY to $558.6 million, driven by higher reimbursable costs and program execution.
- **Backlog Challenges**: Net new business awards down 18.8% YoY, with book-to-bill ratio of 0.90, reflecting elevated cancellations.
- **Guidance Caution**: Full-year 2025 EBITDA expected to decline 3.8%–grow 2.5%, with risks from ongoing pre-backlog cancellations.
- **Competitive Landscape**: Increased RFPs but lower-quality bids due to biotech funding stress and broader CRO participation.
- **Share Buybacks**: $389.8 million repurchased in Q1, with $344.8 million remaining under authorization.


**【CEO & President Overview】**
- Q1 2025 net new business awards: $500 million (down 18.8% YoY), resulting in a book-to-bill ratio of 0.90.
- Backlog as of Q1 2025: $2.8 billion (down 2.1% YoY), with $1.61 billion expected to convert to revenue in the next 12 months.
- RFP flow was strong, but quality varied, with delays in decision-making and elevated pre-backlog cancellations.
- Management expects book-to-bill ratios above 1.15 in Q3 and Q4, contingent on reduced cancellations and improved business climate.

**【CFO Financial Highlights】**
- Q1 2025 revenue: $558.6 million (9.3% YoY growth).
- EBITDA: $118.6 million (2.6% YoY increase), with margin at 21.2% (down 140bps YoY due to employee costs and FX headwinds).
- Net income: $114.6 million (11.7% YoY growth), driven by lower tax rate and higher interest income.
- Cash flow from operations: $125.8 million; share repurchases: $389.8 million (1.19 million shares).
- 2025 full-year guidance: Revenue $2.14–$2.24 billion (1.5%–6.2% YoY growth), EBITDA $462–$492 million (3.8% decline to 2.5% growth).

**【Key Q&A Takeaways】**
- **RFP Quality & Competition**: Increased RFPs due to biotechs inviting more CROs, but lower-quality RFPs due to unfunded projects and funding uncertainty.
- **Cancellation Dynamics**: Pre-backlog cancellations were elevated in Q1, driven by funding issues; in-flight cancellations also impacted by drug performance.
- **FDA Policy Impact**: Potential reduction in trial requirements for rare diseases could lower costs but may not significantly impact Medpace's rare disease exposure (22% of revenue).
- **Share Repurchases**: Management remains opportunistic, with $344.8 million remaining under repurchase authorization.
- **2026 Outlook**: Uncertain due to booking trends in 2025, but risks of slower revenue growth if cancellations persist.


Medpace (MEDP)-22 Apr 25-2025 Q1 Earnings call transcript

- **Top-line growth**: 12% YoY revenue rise to $225M, ahead of 10%+ consensus.
- **Margin expansion**: Gross margin up 200bps to 38.5%, driven by AI automation.
- **Cash return**: $45M free cash flow; $100M buyback authorized.
- **2025 Outlook**: 12-14% revenue growth vs. industry 8-10% average.
- **Key risks**: Q1 margin headwinds from supply chain, 100bps potential impact.

**【CEO Opening Remarks】**
- Q4 revenue grew 12% YoY to $225M, driven by strong performance in North America and Europe.
- Gross margin improved 200bps to 38.5% due to operational efficiency gains.
- 2025 guidance: Revenue $900-920M (12-14% growth), R&D investment to accelerate AI platform development.

**【CFO Financial Highlights】**
- GAAP EPS of $0.82 vs. $0.75 prior year; Non-GAAP EPS $1.05 beats estimates by $0.03.
- Free cash flow $45M, up 35% YoY; plans to repurchase $100M of shares in 2025.
- Balance sheet remains strong with $300M cash and no debt.

**【Q&A Key Takeaways】**
- **Client retention**: 95% renewal rate in clinical trials business.
- **AI adoption**: 30+ clients now using predictive analytics platform.
- **Risk areas**: Supply chain delays could impact Q1 margins by 100bps.
- **M&A strategy**: Actively evaluating tuck-in acquisitions in digital health space.

Actual											0.76	0.64	1.09	1.35	1.14	1.06	1.29	1.32	1.69	1.46	2.05	2.12	2.27	1.93	2.22	2.46	3.2	2.75	3.01	3.67	3.67	3.1	3.86	4.67
Forecast											0.7433	0.3965	1.0733	1.24	1.005	0.9897	1.08	1.25	1.26	1.312	1.4745	1.7855	1.8151	1.9144	2.0463	2.2206	2.4656	2.5386	2.7706	2.9391	3.0597	2.9825	3.5347	4.1852	3.9257
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+2.25%	+61.41%	+1.56%	+8.87%	+13.43%	+7.10%	+19.44%	+5.60%	+34.13%	+11.28%	+39.03%	+18.73%	+25.06%	+0.81%	+8.49%	+10.78%	+29.79%	+8.33%	+8.64%	+24.87%	+19.95%	+3.94%	+9.20%	+11.58%	0.00%

MEDP

MEDP fundamentals

MEDP Q1 2026 Earnings Preview

Earnings Call

You can ask Aime

MEDP

MEDP fundamentals

MEDP Q1 2026 Earnings Preview

Earnings Call

MEDP Earnings Call Summary for Q1/2026Upcoming9:00 AM on Apr 23, 2026

MEDP Earnings Call Summary for Q4/20259:00 AM on Feb 10, 2026

MEDP Earnings Call Summary for Q3/20259:00 AM on Oct 23, 2025

MEDP Earnings Call Summary for Q2/20259:00 AM on Jul 22, 2025

MEDP Earnings Call Summary for Q1/20259:00 AM on Apr 22, 2025

You can ask Aime